Latest news with #LicensingDeals
Yahoo
21-07-2025
- Business
- Yahoo
Dermatology Collaboration and Licensing Agreements Trends Report 2025 with Directory of 474 Deals Since 2016 - Company A-Z, Therapy Focus, Upfront, Milestone, Royalties
Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2025" report has been added to offering. Fully revised and updated, the report provides details of 474 dermatology deals from 2016 to 2025. Dermatology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the dermatology deals entered into by the worlds leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their initial chapters of this report provide an orientation of dermatology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in dermatology 3 covers the financial deal terms for deals signed in the dermatology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty 4 provides a review of the top 25 most active biopharma companies in dermatology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances 5 provides a comprehensive and detailed review of dermatology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on 6 provides a comprehensive directory of dermatology deals listed by therapeutic report also includes numerous table and figures that illustrate the trends and activities in dermatology deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse dermatology collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in dermatology dealmaking2.1. Introduction2.2. Dermatology partnering over the years2.3. Dermatology partnering by deal type2.4. Dermatology partnering by industry sector2.5. Dermatology partnering by stage of development2.6. Dermatology partnering by technology type2.7. Dermatology partnering by therapeutic indicationChapter 3 - Financial deal terms for dermatology partnering3.1. Introduction3.2. Disclosed financials terms for dermatology partnering3.3. Dermatology partnering headline values3.4. Dermatology deal upfront payments3.5. Dermatology deal milestone payments3.6. Dermatology royalty ratesChapter 4 - Leading dermatology deals and dealmakers4.1. Introduction4.2. Most active in dermatology partnering4.3. List of most active dealmakers in dermatology4.4. Top dermatology deals by valueChapter 5 - Dermatology contract document directory5.1. Introduction5.2. Dermatology partnering deals where contract document availableChapter 6 - Dermatology dealmaking by therapeutic target6.1. Introduction6.2. Deals by dermatology therapeutic targetDeal directoryDeal directory - Dermatology deals by company A-Z 2016 to 2025Deal directory - Dermatology deals by technology type 2016 to 2025 For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
21-07-2025
- Business
- Yahoo
Efficiently Identify Immunology Deal Structures and Terms - Upfront, Milestone, Royalties
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not. Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2025" report has been added to offering. Fully revised and updated, the report provides details of 909 immunology deals from 2016 to Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their initial chapters of this report provide an orientation of immunology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in immunology 3 covers the financial deal terms for deals signed in the immunology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty 4 provides a review of the top 25 most active biopharma companies in immunology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances 5 provides a comprehensive and detailed review of immunology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on 6 provides a comprehensive directory of immunology deals listed by therapeutic report also includes numerous table and figures that illustrate the trends and activities in immunology deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse immunology collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Immunology Collaboration and Licensing Deals includes: Trends in immunology dealmaking in the biopharma industry Overview of collaboration and licensing deal structure Directory of immunology deal records covering pharmaceutical and biotechnology The leading immunology deals by value Most active immunology licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in immunology dealmaking2.1. Introduction2.2. Immunology partnering over the years2.3. Immunology partnering by deal type2.4. Immunology partnering by industry sector2.5. Immunology partnering by stage of development2.6. Immunology partnering by technology type2.7. Immunology partnering by therapeutic indicationChapter 3 - Financial deal terms for immunology partnering3.1. Introduction3.2. Disclosed financials terms for immunology partnering3.3. Immunology partnering headline values3.4. Immunology deal upfront payments3.5. Immunology deal milestone payments3.6. Immunology royalty ratesChapter 4 - Leading immunology deals and dealmakers4.1. Introduction4.2. Most active in immunology partnering4.3. List of most active dealmakers in immunology4.4. Top immunology deals by valueChapter 5 - Immunology contract document directory5.1. Introduction5.2. Immunology partnering deals where contract document availableChapter 6 - Immunology dealmaking by therapeutic target6.1. Introduction6.2. Deals by immunology therapeutic targetDeal directoryDeal directory - Immunology deals by company A-Z 2016 to 2025Deal directory - Immunology deals by technology type 2016 to 2025Deal type definitions For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
23-06-2025
- Business
- Business Wire
In-Vitro Diagnostic Collaboration and Licensing Agreements Analysis Report 2025 with Directory of 289 Deals - Upfront, Milestone, Royalties Financial Terms, Company A-Z, Deal Type and Therapy Area
DUBLIN--(BUSINESS WIRE)--The "In Vitro Diagnostic Collaboration and Licensing Deals 2016-2025" has been added to offering. This report contains a comprehensive listing of 289 in vitro diagnostic deals announced since 2016, including financial terms where available, with links to online deal records of actual in vitro diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. In Vitro Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the in vitro diagnostic deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of in vitro diagnostic deals from 2016 to 2025. The report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals. The initial chapters of this report provide an orientation of in vitro diagnostic dealmaking. Chapter 1 provides an introduction to the report, while Chapter 2 offers an overview of the trends in in vitro diagnostic dealmaking since 2016. Chapter 3 highlights the leading in vitro diagnostic deals since 2016, sorted by headline value. Chapter 4 gives a comprehensive listing of the top 25 most active companies in in vitro diagnostic dealmaking, along with a detailed list of deals and available public contract documents. Chapter 5 and Chapter 6 offer a detailed review of deals signed and announced since January 2016, with Chapter 6 focusing specifically on various in vitro diagnostic technology types. The report also includes numerous tables and figures that illustrate trends and activities in in vitro diagnostic dealmaking since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on demand. In Vitro Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse in vitro diagnostic collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time In Vitro Diagnostic Collaboration and Licensing Deals includes: Trends in in vitro diagnostic dealmaking in the biopharma industry Directory of in vitro diagnostic deal records covering pharmaceutical and biotechnology The leading in vitro diagnostic deals by value Most active in vitro diagnostic licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in in vitro diagnostic dealmaking 2.1. Introduction 2.2. In vitro diagnostic deals over the years 2.3. Most active in vitro diagnostic dealmakers 2.4. In vitro diagnostic deals by deal type 2.5. In vitro diagnostic deals by therapy area 2.6. In vitro diagnostic deals by industry sector 2.7. Deal terms for in vitro diagnostic deals 2.7.1 In vitro diagnostic deals headline values 2.7.2 In vitro diagnostic deal upfront payments 2.7.3 In vitro diagnostic deal milestone payments 2.7.4 In vitro diagnostic royalty rates Chapter 3 - Leading in vitro diagnostic deals 3.1. Introduction 3.2. Top in vitro diagnostic deals by value Chapter 4 - Most active in vitro diagnostic dealmakers 4.1. Introduction 4.2. Most active in vitro diagnostic dealmakers 4.3. Most active in vitro diagnostic deals company profiles Chapter 5 - In vitro diagnostic contracts dealmaking directory 5.1. Introduction 5.2. In vitro diagnostic contracts dealmaking directory Chapter 6 - In vitro diagnostic dealmaking by technology type Deal directory Deal directory - In vitro diagnostic deals by company A-Z Deal directory - In vitro diagnostic deals by deal type Deal directory - In vitro diagnostic deals by therapy area Deal type definitions Companies Featured 2cureX 3M 23andMe Abbott Laboratories Actelion Agilent Technologies Alexion Pharmaceuticals AliveCor Allogene Therapeutics American Type Culture Collection (ATCC) Anixa Biosciences AstraZeneca Avacta Bayer Beckman Coulter Bio-Rad Laboratories bioMerieux Biotage Brigham and Women's Hospital Cardiff University Cepheid Cleveland Clinic Columbia University Danaher Dako Eli Lilly Epizyme Fujirebio Diagnostics Genentech Georgetown University Ginkgo BioWorks Guardant Health Hologic Illumina Inova Diagnostics Invitae Janssen Pharmaceuticals Johns Hopkins University Lexent Bio Massachusetts Institute of Technology Mayo Clinic Medigus Memorial Sloan Kettering Cancer Center Monsanto Novartis OraSure Technologies Oxford Nanopore Technologies PerkinElmer Pfizer Qiagen For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
